Paxil CR returns
Executive Summary
GlaxoSmithKline resumes shipment of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities (1"The Pink Sheet" March 21, 2005, p. 15). Sales reps will offer 30-day free trial vouchers to support reintroduction; Paxil CR will be a "priority" for sales force, GSK says. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...
You may also be interested in...
FDA Expects Consent Decree For GSK As Follow-Up To Seizure Action
FDA expects to enter into a consent decree with GlaxoSmithKline to resolve manufacturing violations at its Cidra, Puerto Rico facility following the seizure of Paxil CR and Avandamet
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: